World Investment Advisors LLC Boosts Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

World Investment Advisors LLC lifted its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 44.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,716 shares of the company’s stock after purchasing an additional 1,453 shares during the quarter. World Investment Advisors LLC’s holdings in GE HealthCare Technologies were worth $443,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Quent Capital LLC boosted its holdings in GE HealthCare Technologies by 18.4% during the 3rd quarter. Quent Capital LLC now owns 766 shares of the company’s stock valued at $72,000 after acquiring an additional 119 shares during the period. Greenleaf Trust boosted its holdings in GE HealthCare Technologies by 1.7% during the 3rd quarter. Greenleaf Trust now owns 7,619 shares of the company’s stock valued at $715,000 after acquiring an additional 124 shares during the period. Westside Investment Management Inc. boosted its holdings in GE HealthCare Technologies by 32.0% during the 3rd quarter. Westside Investment Management Inc. now owns 516 shares of the company’s stock valued at $48,000 after acquiring an additional 125 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in GE HealthCare Technologies by 8.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company’s stock valued at $135,000 after acquiring an additional 127 shares during the period. Finally, Quarry LP boosted its holdings in GE HealthCare Technologies by 28.3% during the 2nd quarter. Quarry LP now owns 594 shares of the company’s stock valued at $46,000 after acquiring an additional 131 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GEHC has been the subject of several research analyst reports. UBS Group cut GE HealthCare Technologies from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $84.00 to $74.00 in a report on Thursday, September 26th. BTIG Research raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Wednesday, September 18th. Wells Fargo & Company increased their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Stifel Nicolaus increased their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Finally, JPMorgan Chase & Co. began coverage on GE HealthCare Technologies in a research report on Monday, September 9th. They issued a “neutral” rating and a $90.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, GE HealthCare Technologies presently has an average rating of “Moderate Buy” and an average price target of $95.46.

Insider Transactions at GE HealthCare Technologies

In other news, CEO Roland Rott sold 3,577 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the transaction, the chief executive officer now directly owns 24,298 shares in the company, valued at $2,101,291.04. This trade represents a 12.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Stock Down 1.3 %

GE HealthCare Technologies stock opened at $79.25 on Wednesday. The firm has a market cap of $36.21 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 2.96 and a beta of 1.07. The stock has a fifty day simple moving average of $85.41 and a two-hundred day simple moving average of $83.80. GE HealthCare Technologies Inc. has a 12 month low of $71.31 and a 12 month high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. The business had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the company earned $0.99 EPS. Equities analysts predict that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be paid a $0.035 dividend. This is an increase from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.18%. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.85%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.